BKS Advisors LLC held its stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,500 shares of the life sciences company’s stock at the end of the second quarter. BKS Advisors LLC’s holdings in Illumina were worth $607,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the stock. Nisa Investment Advisors LLC increased its stake in shares of Illumina by 41.0% in the first quarter. Nisa Investment Advisors LLC now owns 6,190 shares of the life sciences company’s stock worth $1,056,000 after buying an additional 1,800 shares during the last quarter. State of Tennessee Treasury Department increased its stake in shares of Illumina by 7.8% in the first quarter. State of Tennessee Treasury Department now owns 97,850 shares of the life sciences company’s stock worth $16,697,000 after buying an additional 7,040 shares during the last quarter. Bank of Nova Scotia increased its stake in shares of Illumina by 265.4% in the first quarter. Bank of Nova Scotia now owns 86,202 shares of the life sciences company’s stock worth $14,710,000 after buying an additional 62,612 shares during the last quarter. Aberdeen Asset Management PLC UK increased its stake in shares of Illumina by 8.4% in the first quarter. Aberdeen Asset Management PLC UK now owns 27,981 shares of the life sciences company’s stock worth $4,775,000 after buying an additional 2,158 shares during the last quarter. Finally, Puzo Michael J increased its stake in shares of Illumina by 0.4% in the second quarter. Puzo Michael J now owns 5,955 shares of the life sciences company’s stock worth $1,032,000 after buying an additional 25 shares during the last quarter. 93.32% of the stock is owned by institutional investors.

Illumina, Inc. (ILMN) opened at 199.74 on Thursday. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $200.00. The firm has a market cap of $29.16 billion, a P/E ratio of 40.08 and a beta of 0.83. The company has a 50-day moving average price of $183.92 and a 200-day moving average price of $176.00.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.14. The business had revenue of $662 million for the quarter, compared to analyst estimates of $642.38 million. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The company’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.86 earnings per share. On average, analysts predict that Illumina, Inc. will post $3.65 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/31/illumina-inc-ilmn-position-held-by-bks-advisors-llc.html.

ILMN has been the subject of a number of research analyst reports. Vetr downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 price target for the company. in a report on Wednesday, June 21st. Barclays PLC reissued a “hold” rating and issued a $150.00 price target on shares of Illumina in a report on Wednesday, July 19th. BidaskClub downgraded shares of Illumina from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 25th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $195.00 price target for the company in a report on Thursday, July 27th. Finally, Canaccord Genuity raised shares of Illumina from a “hold” rating to a “buy” rating and upped their price target for the company from $170.00 to $215.00 in a report on Monday, August 7th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company. Illumina presently has an average rating of “Hold” and a consensus target price of $177.01.

In related news, SVP Charles Dadswell sold 145 shares of the stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $184.75, for a total transaction of $26,788.75. Following the completion of the sale, the senior vice president now directly owns 10,791 shares of the company’s stock, valued at $1,993,637.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jay T. Flatley sold 20,000 shares of the stock in a transaction that occurred on Tuesday, June 6th. The shares were sold at an average price of $180.24, for a total value of $3,604,800.00. Following the sale, the director now directly owns 539,176 shares of the company’s stock, valued at $97,181,082.24. The disclosure for this sale can be found here. In the last quarter, insiders sold 159,945 shares of company stock worth $29,365,458. Corporate insiders own 1.60% of the company’s stock.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.